Who should attend this event?

Healthcare leaders, policymakers, startups and innovators.

Visit the official event page and register online.

Gland Pharma Q2 FY27: Profit Up 58%, CDMO Up 31%

News

Gland Pharma Q2 FY27 Profit Jumps 58% as CDMO Grows 31% By eHealth Network - 07 November 2026

Stainless steel sterile injectables manufacturing line with vessels and piping at a Gland Pharma facility in India.

Gland Pharma Limited reported a 58% year-on-year rise in consolidated net profit to ₹291 crore for the second quarter of FY27 (July–September 2026), as its contract development and manufacturing (CDMO) business grew 31% and US sales climbed 42%. Revenue from operations rose 23% to ₹1,834 crore, the Hyderabad-based injectables maker said in its Q2 FY27 press release on 6 November 2026.

Gland Pharma Q2 FY27 results at a glance

Revenue from operations: ₹1,834 crore, up 23% from ₹1,487 crore a year earlier
EBITDA: ₹480 crore, up 53%, with margin widening to 26% from 21%
Adjusted EBITDA: ₹503 crore, up 50%, at a 27% margin
Net profit (PAT): ₹291 crore, up 58% from ₹184 crore; PAT margin up about 350 basis points to 16%
R&D spend: ₹108 crore, or 6% of revenue

Sequentially, revenue grew 2% over Q1 FY27, while profit after tax was 8% lower than the ₹317 crore reported in the June quarter. For the first half of FY27, revenue rose 21% to ₹3,634 crore and net profit grew 52% to ₹608 crore.

CDMO and critical injectables drive growth

The CDMO business contributed 45% of quarterly revenue and grew 31% year-on-year, while the critical injectables business, covering B2B and B2C sales, made up the remaining 55% and grew 18%. Contract manufacturing has become a key growth engine for Indian drugmakers this earnings season, as seen in Akums’ Q2 FY27 CDMO performance.

“We delivered another quarter of strong growth, with revenue increasing 23% year-on-year and profit after tax growing 58% year-on-year, driven by strong execution across our businesses,” said Srinivas Sadu, Executive Chairman of Gland Pharma. He added that the CDMO business was “supported by expanding customer engagements, strategic partnerships and a robust opportunity pipeline.”

US market leads the geographic mix

The United States remained Gland’s largest market, with revenue of about ₹1,180 crore in the quarter, up 42% year-on-year, according to the company’s earnings call disclosures. Europe and other regulated markets grew 23% to about ₹411 crore, while Rest of World sales were affected by a tender delay in Saudi Arabia. During the quarter the company filed 11 ANDAs, received 10 approvals and made four US launches, building on approvals such as its USFDA nod for generic Depo-Medrol injection.

Its European subsidiary Cenexi posted revenue of about EUR 41 million but a negative EBITDA of EUR 6 million because of planned annual shutdowns; management expects it to turn profitable from the third quarter.

Capacity expansion and cash position

Gland said its ₹2,000 crore capacity expansion programme remains on track, including a roughly ₹1,000 crore brownfield expansion at Pashamylaram expected to begin commercial operations in FY30. The company held cash and cash equivalents of about ₹3,441 crore as of 30 September 2026, with a net cash position of about ₹3,222 crore.

The results add to a strong set of Q2 FY27 numbers from Indian pharma companies, including Aurobindo Pharma’s record quarterly revenue and Granules India’s 39% profit rise.

Key takeaways

Gland Pharma’s Q2 FY27 net profit rose 58% to ₹291 crore on 23% revenue growth.
CDMO revenue grew 31% and now makes up 45% of the business.
US revenue rose 42%, while Cenexi remained loss-making at the EBITDA level due to planned shutdowns.

Frequently asked questions

What was Gland Pharma’s Q2 FY27 net profit?

Gland Pharma reported a consolidated net profit of ₹291 crore for Q2 FY27, up 58% from ₹184 crore in Q2 FY26.

How much did Gland Pharma’s CDMO business grow?

The CDMO business grew 31% year-on-year and contributed 45% of the company’s Q2 FY27 revenue.

When will the Pashamylaram expansion start operations?

Gland expects commercial operations at the brownfield Pashamylaram expansion to begin in FY30.

Also read: Lupin Q2 FY27: Sales Rise 14% but Net Profit Falls 22%

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!